• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senate bill looks to block tribal patent deals with pharma

March 8, 2018 By Sarah Faulkner

AllerganMonths after Allergan (NYSE:AGN) struck a controversial patent deal with a Native American tribe in New York, lawmakers are angling to make sure that it can’t happen again.

Sens. Tom Cotton (R-Ar), Claire McCaskill (D-Mo) David Perdue (R-Ga), Joni Ernst (R-Ia) and Pat Toomey (R-Pa) introduced a bill this week that would prevent patent owners from claiming sovereign immunity as a means to shield IP from review by the U.S. Patent and Trademark Office.

In September last year, Allergan inked a deal with the St. Regis Mohawk tribe to transfer the patents for its blockbuster eye drug, Restasis, in an attempt to halt any review by the USPTO. The tribe agreed to license the patents exclusively to the company in exchange for payments.

Both parties have argued that the tribe’s sovereign immunity renders the patents outside of the trademark office’s power of review.

The deal struck a nerve around the pharmaceutical industry and with lawmakers. Mylan (NSDQ:MYL) criticized Allergan for gaming the U.S. patent system, while other companies called Allergan CEO Brent Saunders hypocritical in light of the “social contract” he issued over drug pricing in 2016.

Earlier this year, Allergan said it planned to cut more than 5% of its workforce in a cost-cutting effort as it faces competition from up-coming generics to Restasis.

The company anticipates taking a $125 million hit from the job cuts, the majority of which will be noted in the fourth quarter of the 2017 fiscal year.

The cost savings from its restructuring program should be between $300 – $400 million per year, according to Allergan.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Allergan, Mylan

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS